{"id":"trexan-salazopyrin-oxiklorin-prednisolone-infliximab","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection (including serious infections)"},{"rate":null,"effect":"Bone marrow suppression"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Gastrointestinal disturbance"},{"rate":null,"effect":"Immunosuppression-related complications"}]},"_chembl":{"chemblId":"CHEMBL1201581","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Trexan (methotrexate) inhibits dihydrofolate reductase and suppresses T-cell proliferation. Salazopyrin (sulfasalazine) reduces intestinal inflammation and modulates immune function. Prednisolone is a corticosteroid that broadly suppresses inflammation. Infliximab is a TNF-alpha inhibitor monoclonal antibody that blocks a key pro-inflammatory cytokine. Together, these agents target multiple pathways in inflammatory and autoimmune disease.","oneSentence":"This combination therapy suppresses inflammatory and immune responses through multiple mechanisms including methotrexate-induced immunosuppression, sulfasalazine's anti-inflammatory effects, corticosteroid action, and TNF-alpha inhibition via infliximab.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:14:24.066Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Inflammatory bowel disease"}]},"trialDetails":[{"nctId":"NCT01015547","phase":"PHASE3","title":"Aggressive Combination Drug Therapy in Very Early Polyarticular Juvenile Idiopathic Arthritis","status":"COMPLETED","sponsor":"Helsinki University Central Hospital","startDate":"2003-05","conditions":"Juvenile Idiopathic Arthritis","enrollment":60},{"nctId":"NCT00908089","phase":"PHASE4","title":"TNF-blocking Therapy in Combination With Disease-modifying Antirheumatic Drugs in Early Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"University of Helsinki","startDate":"2003-03","conditions":"Rheumatoid Arthritis","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":16904,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Trexan, Salazopyrin, Oxiklorin, Prednison, Remicade"],"phase":"marketed","status":"active","brandName":"Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab","genericName":"Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab","companyName":"University of Helsinki","companyId":"university-of-helsinki","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination therapy suppresses inflammatory and immune responses through multiple mechanisms including methotrexate-induced immunosuppression, sulfasalazine's anti-inflammatory effects, corticosteroid action, and TNF-alpha inhibition via infliximab. Used for Rheumatoid arthritis, Inflammatory bowel disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}